Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Gynecologic 5NET 4Endocrine 4Thoracic 3Genitourinary 3Tumor-Agnostic 1Myeloid 1CNS 1

Conditions

Neuroendocrine Tumors 4

Interventions

Everolimus 18lutetium Lu 177 dotatate 9lanreotide 8surufatinib 7Octreotide 7pasireotide 5amino-acid, glucose, and electrolyte solution 5Sunitinib 5Temozolomide 4Data Collection 4pembrolizumab 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2fosbretabulin 2arginyllysine 2anlotinib 2Paclitaxel 2PM 01183 2Lutetium-177 2Lutetium 2Irinotecan 2Injections 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Data Collection × NET × Clear all
NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03562091 2020-08-28

OPERA

Ipsen

Completed
115 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03112694 2020-06-02

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Ipsen

Completed
93 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03220087 2018-12-21

RECOSY

Ipsen

Completed
142 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡